These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16857743)

  • 1. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
    Ezzat S; Zheng L; Winer D; Asa SL
    Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia.
    Ezzat S; Zheng L; Asa SL
    Mol Endocrinol; 2004 Oct; 18(10):2543-52. PubMed ID: 15231874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness.
    Qian ZR; Sano T; Asa SL; Yamada S; Horiguchi H; Tashiro T; Li CC; Hirokawa M; Kovacs K; Ezzat S
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1904-11. PubMed ID: 15070963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
    Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth.
    Ezzat S; Huang P; Dackiw A; Asa SL
    Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
    Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
    Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis.
    Ezzat S; Zheng L; Zhu XF; Wu GE; Asa SL
    J Clin Invest; 2002 Jan; 109(1):69-78. PubMed ID: 11781352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5' fibroblast growth factor receptor-4 promoter.
    Ezzat S; Yu S; Asa SL
    Am J Pathol; 2003 Sep; 163(3):1177-84. PubMed ID: 12937159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors.
    Ezzat S; Wang R; Pintilie M; Asa SL
    Oncotarget; 2017 Jan; 8(2):3481-3494. PubMed ID: 27966451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
    Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
    Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
    Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
    Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.
    St Bernard R; Zheng L; Liu W; Winer D; Asa SL; Ezzat S
    Endocrinology; 2005 Mar; 146(3):1145-53. PubMed ID: 15564323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4.
    Yu S; Asa SL; Weigel RJ; Ezzat S
    J Biol Chem; 2003 May; 278(22):19597-602. PubMed ID: 12642581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
    Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
    Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
    Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of fibroblast growth factor receptors in human pituitary adenomas.
    Abbass SA; Asa SL; Ezzat S
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1160-6. PubMed ID: 9100589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.